|By PR Newswire||
|August 14, 2014 02:11 PM EDT||
BERGISCH GLADBACH, Germany, August 14, 2014 /PRNewswire/ --
Addition of lentiviral gene delivery capabilities complements strategic partnering portfolio.
Miltenyi Biotec announced today that it has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications.
The acquisition further strengthens Miltenyi Biotec's portfolio in cell and gene therapy. Assets obtained in the transaction include a broad range of intellectual property, process technologies, and cGMP-qualified manufacturing facilities. The Lentigen team will join Miltenyi Biotec, and operate through its newly formed, wholly owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.
Miltenyi Biotec will leverage the combined capabilities by offering customized system and application design in strategic partnerships with clinical investigators and companies to develop and commercialize cell and gene therapies.
"It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors for cell and gene therapies, both for clinical research and at commercial scale," said Stefan Miltenyi, Chief Executive Officer of Miltenyi Biotec. "With the acquisition of the Lentigen assets, we have strengthened our comprehensive portfolio that will enable our current and future partners to proceed in cell therapies efficiently from preclinical testing through human studies to automated manufacturing for widespread commercial therapeutic use, all with a single strategic partner."
Lentiviral technology provides the most efficient method for delivering genetic material into cells to modulate their function, as demonstrated by recent clinical trials in genetic diseases and oncology indications utilizing lentivirus-modified chimeric antigen receptor (CAR) T cells.
Concurrent with the transaction, the sellers, now operating as Opus Bio, Inc., have been granted certain rights to deploy lentiviral technology in some therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.
About Miltenyi Biotec
Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company's integrated tools support research at every level, from basic research to translational research to clinical application. Their technologies cover techniques of sample preparation, cell isolation, flow sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. The company's more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. Trusted around the world, the Miltenyi Biotec brand continues to set new standards in the industry. Miltenyi Biotec has more than 1,400 employees in 25 countries.
SOURCE Miltenyi Biotec
May. 3, 2015 09:00 AM EDT Reads: 1,013
May. 3, 2015 09:00 AM EDT Reads: 3,880
May. 3, 2015 09:00 AM EDT Reads: 666
May. 3, 2015 08:45 AM EDT Reads: 1,144
May. 3, 2015 08:30 AM EDT Reads: 4,446
May. 3, 2015 08:15 AM EDT Reads: 2,973
May. 3, 2015 08:00 AM EDT Reads: 1,631
May. 3, 2015 08:00 AM EDT Reads: 1,715
May. 3, 2015 07:45 AM EDT Reads: 874
May. 3, 2015 07:00 AM EDT Reads: 668
May. 3, 2015 06:00 AM EDT Reads: 4,650
May. 3, 2015 05:00 AM EDT Reads: 5,640
May. 3, 2015 02:45 AM EDT Reads: 5,696
May. 3, 2015 02:00 AM EDT Reads: 2,368
SYS-CON Events announced today that Blue Box has been named “Bronze Sponsor” of SYS-CON's DevOps Summit New York, which will take place June 9-11, 2015, at the Javits Center in New York City, NY. Blue Box delivers Private Cloud as a Service (PCaaS) to a worldwide customer base. Built on a technology platform leveraging decades of operational expertise in cloud and distributed systems, Blue Box Cloud is a managed private cloud product available in both hosted and on-prem versions. Each Blue Box ...
May. 3, 2015 12:00 AM EDT Reads: 1,850